Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZWWNM
ADC Name
CD33-D Antibody-Compound (XIV)
Synonyms
CD33-D Antibody Compound (XIV)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
1-2
Structure
Antibody Name
CD33-D Anti-ody
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CD33-D Antibody-Compound (XIV) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.22
nM
MV4-11 cells
Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.22 nM Positive CD33 expression (CD33+++/++)
Method Description
The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model Childhood acute monocytic leukemia MV4-11 cells CVCL_0064
References
Ref 1 Linkers for use in antibody drug conjugates; 2023-03-16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.